View printer-friendly version |
<< Back |
Mr. Rogers has more than 25 years of experience in the biopharmaceutical
industry, serving as Chief Financial Officer (CFO) of five
publicly-traded healthcare companies. He most recently served as CFO at
“I’m very excited to join Aerpio and work with the existing management team to develop and commercialize first-in-class products which activate the Tie-2 pathway,” said Mr. Rogers. “Aerpio has created significant value through understanding the science behind the Tie-2 pathway. Our leading drug candidate, AKB-9778, represents an important target not only in ophthalmology, but in the pathogenesis of “leaky vasculature” which produces significant morbidity in patients with diabetes and other medical conditions.”
“Mr. Rogers’ strong background in both biotechnology and finance, as
well as his numerous relationships within the investment community make
him an excellent choice to lead our finance efforts,” stated Dr.
About
Forward Looking Statements
This press release contains forward-looking statements. Statements in
this press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
the future plans of the Company, the appointment of Mr. Rogers as the
Company’s Chief Financial Officer, the development of the Company’s
product candidates, including AKB-9778 for non-proliferative diabetic
retinopathy or otherwise, and the therapeutic potential of the Company’s
product candidates, including AKB-9778. Actual results could differ from
those projected in any forward-looking statements due to several risk
factors. Such factors include, among others, the ability to raise the
additional funding needed to continue to develop AKB-9778 or other
product development plans, the inherent uncertainties associated with
the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171114005665/en/
Source:
Investor & Media:
Aerpio
Pharmaceuticals, Inc.
Dhaval Desai
Vice President of
Medical Affairs
ddesai@aerpio.com
or
Burns
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Media:
Justin
Jackson
jjackson@burnsmc.com
or
Investors:
Ami
Bavishi
abavishi@burnsmc.com